SG Americas Securities
ENTA icon

SG Americas Securities’s Enanta Pharmaceuticals ENTA Stock Holding History

SG Americas Securities’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,574
Closed -$132K – 2971
2024
Q1 		$132K Sell
7,574
-2,588
-25% -$34.2K ﹤0.01% 2325
2023
Q4 		$96K Sell
10,162
-8,384
-45% -$78.1K ﹤0.01% 2779
2023
Q3 		$207K Sell
18,546
-41,089
-69% -$662K ﹤0.01% 2304
2023
Q2 		$1.28M Buy
59,635
+17,222
+41% +$508K 0.01% 950
2023
Q1 		$1.72M Buy
42,413
+23,165
+120% +$1.11M 0.02% 763
2022
Q4 		$895K Buy
19,248
+10,815
+128% +$493K 0.01% 1052
2022
Q3 		$437K Sell
8,433
-16,435
-66% -$960K 0.01% 1666
2022
Q2 		$1.18M Sell
24,868
-2,153
-8% -$117K 0.01% 1152
2022
Q1 		$1.92M Buy
27,021
+24,153
+842% +$1.57M 0.01% 943
2021
Q4 		$214K Sell
2,868
-50,131
-95% -$3.93M ﹤0.01% 2639
2021
Q3 		$3.01M Buy
52,999
+7,225
+16% +$357K 0.01% 924
2021
Q2 		$2.02M Sell
45,774
-3,152
-6% -$154K 0.01% 1119
2021
Q1 		$2.41M Buy
48,926
+3,263
+7% +$163K 0.01% 925
2020
Q4 		$1.92M Buy
45,663
+9,491
+26% +$418K 0.01% 1114
2020
Q3 		$1.66M Buy
36,172
+23,113
+177% +$1.12M 0.01% 862
2020
Q2 		$656K Buy
13,059
+8,675
+198% +$449K 0.01% 1826
2020
Q1 		$225K Sell
4,384
-2,113
-33% -$113K ﹤0.01% 2425
2019
Q4 		$401K Sell
6,497
-10,529
-62% -$653K ﹤0.01% 1955
2019
Q3 		$1.02M Buy
17,026
+15,697
+1,181% +$1.17M 0.01% 1393
2019
Q2 		$112K Sell
1,329
-624
-32% -$56.1K ﹤0.01% 2748
2019
Q1 		$187K Sell
1,953
-4,956
-72% -$445K ﹤0.01% 2618
2018
Q4 		$489K Buy
+6,909
New +$530K ﹤0.01% 1878
2018
Q3 		– Sell
-1,795
Closed -$208K – 3229
2018
Q2 		$208K Buy
1,795
+405
+29% +$40.4K ﹤0.01% 2580
2018
Q1 		$112K Buy
+1,390
New +$107K ﹤0.01% 2864
2017
Q4 		– Sell
-5,662
Closed -$265K – 3305
2017
Q3 		$265K Buy
5,662
+1,308
+30% +$52.6K ﹤0.01% 2350
2017
Q2 		$157K Buy
4,354
+237
+6% +$7.58K ﹤0.01% 2593
2017
Q1 		$127K Sell
4,117
-3,841
-48% -$120K ﹤0.01% 2807
2016
Q4 		$267K Buy
+7,958
New +$228K ﹤0.01% 2136
2015
Q2 		– Sell
-3,379
Closed -$103K – 2655
2015
Q1 		$103K Buy
3,379
+1,195
+55% +$46.5K ﹤0.01% 2268
2014
Q4 		$111K Buy
+2,184
New +$97.8K ﹤0.01% 2843

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SG Americas Securities's ENTA Position: Q2 2024 in Review

SG Americas Securities sold out of Enanta Pharmaceuticals (ENTA) in Q2 2024, closing a stake of 7,574 shares — an estimated $132K sold.

SG Americas Securities first reported a position in ENTA in Q4 2014 and held it in 30 quarters. The position peaked at $3.01M in Q3 2021. 100 funds tracked by Wall St. Rank hold ENTA as of Q2 2024.

  • SG Americas Securities reported no remaining Enanta Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • SG Americas Securities sold 7,574 Enanta Pharmaceuticals shares in Q2 2024, an estimated $132K.
  • SG Americas Securities first reported a position in Enanta Pharmaceuticals in Q4 2014 and held it in 30 quarters.
  • SG Americas Securities's Enanta Pharmaceuticals position peaked at $3.01M in Q3 2021.
  • 100 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2024.

Based on SG Americas Securities's 13F filing for Q2 2024, filed 12 Jul 2024.